Cabaletta Bio Q4/FY2025 cash $133.6M; myositis BLA on track for 2027; $30M raise

Cabaletta Bio, Inc.

Q4 R&D expenses $36.2M, FY R&D $142.7M; cash $133.6M as of Dec 31, 2025; raised additional $30M in Q1 2026.
Registrational DM/ASyS cohort enrolling (17 patients); BLA submission for rese-cel in myositis targeted for 2027.
No-preconditioning rese-cel data from RESET-SLE expected 1H26 (initial) and 2H26 (durability); PV durability data throughout 2026.
Automated manufacturing with Cellares: initial clinical data expected 1H26; potential to produce for thousands per year.
Complete Phase 1/2 data from RESET-SSc, RESET-SLE, RESET-MG to be presented in 1H26; design updates for SSc in 1H26 and MG mid-2026.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cabaletta Bio, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.

Period: the fourth quarter and full year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 23, 2026, Cabaletta Bio, Inc. (the "Company") announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.

View on SEC.gov

308 earnings releases filed in the last 30 days. Browse all earnings releases →

Cabaletta Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001759138-26-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.